Rhumbline Advisers purchased a new position in Amyris Inc (NASDAQ:AMRS) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 23,077 shares of the biotechnology company’s stock, valued at approximately $147,000.
A number of other large investors have also recently made changes to their positions in the business. Millennium Management LLC bought a new position in Amyris in the first quarter worth approximately $1,643,000. JPMorgan Chase & Co. bought a new position in Amyris in the first quarter worth approximately $655,000. Engineers Gate Manager LP bought a new position in Amyris in the second quarter worth approximately $413,000. KBC Group NV boosted its holdings in Amyris by 37.4% in the first quarter. KBC Group NV now owns 62,465 shares of the biotechnology company’s stock worth $418,000 after acquiring an additional 16,995 shares in the last quarter. Finally, BlackRock Inc. boosted its holdings in Amyris by 139.2% in the first quarter. BlackRock Inc. now owns 53,414 shares of the biotechnology company’s stock worth $358,000 after acquiring an additional 31,083 shares in the last quarter. Institutional investors and hedge funds own 27.90% of the company’s stock.
Shares of Amyris stock opened at $7.82 on Thursday. Amyris Inc has a 52 week low of $2.82 and a 52 week high of $9.22. The company has a debt-to-equity ratio of -0.24, a quick ratio of 0.38 and a current ratio of 0.42.
Amyris (NASDAQ:AMRS) last issued its quarterly earnings data on Monday, August 6th. The biotechnology company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.08). The firm had revenue of $24.81 million during the quarter, compared to analysts’ expectations of $37.52 million. The firm’s revenue was down 3.4% on a year-over-year basis. During the same period in the previous year, the business posted ($1.32) earnings per share. analysts predict that Amyris Inc will post -1.41 EPS for the current fiscal year.
Several analysts have recently commented on AMRS shares. B. Riley set a $10.00 price objective on Amyris and gave the stock a “buy” rating in a research note on Monday, September 17th. HC Wainwright set a $15.00 price objective on Amyris and gave the stock a “buy” rating in a research note on Monday, September 17th. BidaskClub raised Amyris from a “hold” rating to a “buy” rating in a research note on Wednesday, August 15th. Zacks Investment Research downgraded Amyris from a “hold” rating to a “sell” rating in a research note on Thursday, August 9th. Finally, ValuEngine raised Amyris from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 2nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $9.13.
In related news, Director Patrick Y. Yang acquired 10,000 shares of the stock in a transaction dated Thursday, August 9th. The stock was purchased at an average cost of $7.71 per share, with a total value of $77,100.00. Following the completion of the purchase, the director now directly owns 36,932 shares in the company, valued at approximately $284,745.72. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider John Melo sold 22,355 shares of the stock in a transaction that occurred on Monday, July 16th. The shares were sold at an average price of $6.61, for a total value of $147,766.55. Following the sale, the insider now directly owns 748,908 shares of the company’s stock, valued at $4,950,281.88. The disclosure for this sale can be found here. Over the last three months, insiders bought 50,877 shares of company stock valued at $393,161 and sold 8,824,625 shares valued at $54,897,886. Corporate insiders own 21.80% of the company’s stock.
Amyris Company Profile
Amyris, Inc provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market.
Featured Article: What are the reasons investors use put options?
Want to see what other hedge funds are holding AMRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amyris Inc (NASDAQ:AMRS).
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.